Tablets having discontinuous coated regions

1 . A dosage form suitable for ingestion by a human, comprising:

a tablet- or caplet-shaped substrate; and

at least two discontinuous coated regions positioned on a surface of the tablet- or caplet-shaped substrate, wherein said at least two discontinuous coated regions confer an observable benefit to its user, wherein one discontinuous coated region comprises citric acid and one discontinuous coated region comprises sodium bicarbonate.

2 . The dosage form of claim 1 , wherein said at least two discontinuous coated regions affect at least one sense of said user, wherein said at least one sense is selected from group consisting of hearing, sight, touch, smell, and taste.

3 . The dosage form of claim 1 , wherein said at least two discontinuous coated regions comprise at least one agent selected from the group consisting of sensate, salivant, flavor and sweetener.

4 . The dosage form of claim 1 , wherein at least one of said at least two discontinuous coated regions aids swallowability of said dosage form.

5 . The dosage form of claim 1 , wherein at least one of said at least two discontinuous coated regions comprises at least one lubricious material.

6 . The dosage form of claim 1 , wherein said at least two discontinuous coated regions comprise a visual selected from the group consisting of configuration, color and marking that conveys attributes of the dosage form to said user.

7 . The dosage form of claim 1 , wherein at least three discontinuous coated regions are positioned on the surface of the tablet- or caplet-shaped substrate.

8 . The dosage form of claim 1 , wherein the tablet- or caplet-shaped substrate is cylindrical in shape.

9 . The dosage form of claim 8 , wherein the at least two discontinuous coated regions concentrically surround the surface of the tablet- or caplet-shaped substrate.

10 . The dosage form of claim 9 , wherein the tablet- or caplet-shaped substrate is angled at at least one end, and wherein at least one of the at least two discontinuous coated regions covers a portion of the angled end.

11 . The dosage form of claim 8 , wherein the at least two discontinuous coated regions are positioned longitudinally on the tablet- or caplet-shaped substrate.

12 . The dosage form of claim 1 , wherein the tablet- or caplet-shaped substrate comprises at least one active agent.

13 . The dosage form of claim 1 , wherein at least three to at least ten discontinuous coated regions are positioned on the surface of the tablet- or caplet-shaped substrate.

14 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions contain at least one flavoring or sensate, and wherein each of the at least two discontinuous coated regions contain a separate flavoring or sensate.

15 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are extrusion coated on the tablet- or caplet-shaped substrate.

16 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are screen coated on the tablet- or caplet-shaped substrate.

17 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are printed on the tablet- or caplet-shaped substrate.

18 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are brush coated on the tablet- or caplet-shaped substrate.

19 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are sprayed on the tablet- or caplet-shaped substrate.

20 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are painted on the tablet- or caplet-shaped substrate.

21 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions are 3D printed on the tablet- or caplet-shaped substrate.

22 . The dosage form of claim 1 , wherein the at least two discontinuous coated regions comprise a material selected from the group consisting of polymers, meltable carbohydrates, fats, fatty acid esters, phospholipids, waxes, and gelling material,

wherein the fats are selected from the group consisting of hydrogenated vegetable oils selected from cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil; and free fatty acids and their salts,

wherein the fatty acid esters are selected from the group consisting of sucrose fatty acid esters, mono, di, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tristearate, glyceryl trilaurylate, glyceryl myristate, glyceryl tristearate, lauroyl macrogol-32 glycerides, and stearoyl macrogol-32 glycerides,

wherein the phospholipids are selected from the group consisting of phosphatidyl choline, phosphatidyl serine, phosphatidyl inositol, and phosphatidic acid,

wherein the waxes are selected from the group consisting of carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax,

wherein the polymers are selected from the group consisting of polyethylene oxide, polyvinyl acetate and polycaprolactone; and water soluble film forming polymers selected from hydroxypropyl cellulose, hypromellose, methylcellulose, pullulan, modified starches, and hydroxyethylcellulose,

wherein the carbohydrate is selected from the group consisting of polysaccharides selected from polyfructose, polydextrose, inulin, hydrogen starch hydrolysate; isomalt; and sugar alcohols selected from as xylitol, sorbitol, erythritol, and mixtures thereof, and

wherein the gelling material is selected from the group consisting of gelatin, pectin, gellan gum, carrageenan, and xanthan gum.

23 . The dosage form of claim 1 , wherein at least one of the at least two discontinuous coated regions comprises an active agent.

24 . The dosage form of claim 1 , wherein the tablet- or caplet-shaped substrate and at least one of the at least two discontinuous coated regions each comprise an active agent.